---
document_datetime: 2025-03-19 15:40:53
document_pages: 23
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/pandemic-influenza-vaccine-h5n1-astrazeneca-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: pandemic-influenza-vaccine-h5n1-astrazeneca-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 11.8900303
conversion_datetime: 2025-12-24 01:08:48.831746
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

## Pandemic influenza vaccine H5N1 AstraZeneca

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                    |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0074               | Renewal of the marketing authorisation. | 30/01/2025                          | 12/03/2025                                  | SmPC and PL                      | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |     | renewal of the conditional MA for Pandemic influenza vaccine H5N1 AstraZeneca, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion.   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/2796             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a | 30/01/2025 | n/a |                                                                                                                                                                              |
| PSUSA/10501 /202405 | Periodic Safety Update EU Single assessment - pandemic influenza vaccine (H5N1) (live attenuated, nasal)                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 16/01/2025 | n/a | PRAC Recommendation - maintenance                                                                                                                                            |
| IG/1811/G           | This was an application for a group of variations. B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.e.5.b - Change in pack size of the finished product - Deletion of a pack size(s)                                                                                                                                                                                                                                                                                                                                                                     | 18/12/2024 | n/a |                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| PSUSA/10501 /202311   | Periodic Safety Update EU Single assessment - pandemic influenza vaccine (H5N1) (live attenuated, nasal)                                                                                                                                                                                                                                                                                                                                                                                | 13/06/2024   | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0071                | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 22/02/2024   | 19/04/2024 | SmPC, Annex II and PL | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Pandemic influenza vaccine H5N1 AstraZeneca, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |
| PSUSA/10501 /202305   | Periodic Safety Update EU Single assessment - pandemic influenza vaccine (H5N1) (live attenuated, nasal)                                                                                                                                                                                                                                                                                                                                                                                | 11/01/2024   | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| WS/2581/G             | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or | 30/11/2023   | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| WS/2579/G   | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure   | 09/11/2023   | n/a   |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| WS/2578     | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits                                                                                                                                                                                                                                  | 09/11/2023   | n/a   |
| IA/0069     | B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 11/10/2023   | n/a   |
| IB/0065/G   | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                         | 02/08/2023   | n/a   |

<div style=\"page-break-after: always\"></div>

|                     | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                        |            |     |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10501 /202211 | Periodic Safety Update EU Single assessment - pandemic influenza vaccine (H5N1) (live attenuated, nasal)                                                                                                                                                                                                                                                                                   | 08/06/2023 | n/a | PRAC Recommendation - maintenance |
| WS/2466             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                          | 01/06/2023 | n/a |                                   |
| WS/2454             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.1.e - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a specification parameter which may have a significant effect on the overall quality of the AS and/or the FP | 25/05/2023 | n/a |                                   |
| WS/2447/G           | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.c.3.z - Change in source of an excipient or                                                                                                                                                                                   | 14/04/2023 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|           | with TSE risk - Other variation - Change in source of an excipient or with TSE risk - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            | reagent B.II.c.3.z reagent   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------------|
| IA/0064   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 22/03/2023 | n/a        |                              |
| R/0057    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 26/01/2023 | 09/03/2023 |                              |
| WS/2385/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test at the site is a biol/immunol method | 09/02/2023 | n/a        | method                       |
| WS/2391   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other                                                                                                                                                                                                                                                                                                                                                                                                      | 02/02/2023 | n/a        |                              |

<div style=\"page-break-after: always\"></div>

|                     | changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |     |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| WS/2388/G           | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test | 26/01/2023 | n/a |                                   |
| PSUSA/10501 /202205 | Periodic Safety Update EU Single assessment - pandemic influenza vaccine (H5N1) (live attenuated, nasal)                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 12/01/2023 | n/a | PRAC Recommendation - maintenance |
| WS/2340/G           | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                | 10/11/2022 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|           | B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol                                                                                                                                                                                                                                       |            |            |                        |                    |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------|
| IA/0055   | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                             | 01/11/2022 | n/a        |                        |                    |
| IB/0054   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                   | 04/10/2022 | 09/03/2023 | SmPC, Labelling and PL |                    |
| IA/0051/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) | 13/07/2022 | n/a        |                        |                    |
| WS/2219/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. to in-process tests or limits                                                                                                                                                                                                                                                                                                            | 07/07/2022 | n/a        |                        | B.I.a.4.z - Change |

<div style=\"page-break-after: always\"></div>

|           | applied during the manufacture of the AS - Other variation B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                           |            |            |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|
| IB/0049   | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                            | 29/04/2022 | n/a        |
| II/0048/G | This was an application for a group of variations. B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 22/04/2022 | n/a        |
| R/0047    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                               | 27/01/2022 | 04/03/2022 |
| WS/2182/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method                                | 16/12/2021 | n/a        |

<div style=\"page-break-after: always\"></div>

|                     | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting   |            |     |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10501 /202105 | Periodic Safety Update EU Single assessment - pandemic influenza vaccine (H5N1) (live attenuated, nasal)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 02/12/2021 | n/a | PRAC Recommendation - maintenance |
| IA/0046             | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 05/11/2021 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|           | procedure                                                                                                                                                                                                                                                                                            |            |            |                                  |                                             |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------------------------------------------|
| WS/2079/G | for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.1.z - Change in the specification parameters excipient - Other variation | 24/06/2021 | n/a        |                                  | This was an application and/or limits of an |
| IB/0042   | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                           | 14/05/2021 | 04/03/2022 | SmPC, Annex II, Labelling and PL |                                             |
| IA/0043   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                         | 07/05/2021 | n/a        |                                  |                                             |
| R/0040    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                              | 28/01/2021 | 10/03/2021 |                                  |                                             |
| WS/1943/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process                                       | 14/01/2021 | n/a        |                                  | of the AS                                   |

<div style=\"page-break-after: always\"></div>

|                     | B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |             |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| WS/1942/G           | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation | 14/01/2021 | n/a        |             |                                   |
| PSUSA/10501 /202005 | Periodic Safety Update EU Single assessment - pandemic influenza vaccine (H5N1) (live attenuated, nasal)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 14/01/2021 | n/a        |             | PRAC Recommendation - maintenance |
| IB/0036             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 09/10/2020 | 10/03/2021 | SmPC and PL |                                   |

<div style=\"page-break-after: always\"></div>

| WS/1809/G   | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process AS   | 09/07/2020   | n/a        |                                  | of the   |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|----------|
| WS/1824     | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.c.z - Change in control of excipients in the Product - Other variation                                                                                                                                                            | 25/06/2020   | n/a        |                                  | Finished |
| IB/0032/G   | This was an application for a group of variations. B.II.e.6.a - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that affects the product information C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                             | 25/03/2020   | 10/03/2021 | SmPC, Annex II, Labelling and PL |          |
| R/0031      | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                              | 30/01/2020   | 16/03/2020 |                                  |          |

<div style=\"page-break-after: always\"></div>

| WS/1739             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.z - Quality change - Active substance - Other variation                                                                         | 12/12/2019   | n/a   |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| PSUSA/10501 /201905 | Periodic Safety Update EU Single assessment - pandemic influenza vaccine (H5N1) (live attenuated, nasal)                                                                                                                                                                          | 28/11/2019   | n/a   | PRAC Recommendation - maintenance |
| IG/1142             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                     | 11/09/2019   | n/a   |                                   |
| IG/1143             | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                            | 26/08/2019   | n/a   |                                   |
| WS/1646             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 25/07/2019   | n/a   |                                   |
| IG/1115/G           | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                  | 28/06/2019   | n/a   |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer for importation and/or batch release - including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |                 | B.II.b.2.c.1 responsible Not   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|--------------------------------|
| R/0019    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 28/02/2019 | 17/04/2019 |                 |                                |
| IB/0023/G | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer | 28/03/2019 | 16/03/2020 | Annex II and PL |                                |

<div style=\"page-break-after: always\"></div>

|           | Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |     |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| WS/1533   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                   | 14/02/2019 | n/a |
| WS/1552   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                  | 14/02/2019 | n/a |
| II/0020/G | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch | 14/02/2019 | n/a |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| control/testing takes place method at the site is a B.I.a.2.a - Changes in the AS - Minor change of the AS B.I.a.2.b - Changes in the AS - Substantial change process of the AS which impact on the quality, medicinal product B.I.a.2.z - Changes in the AS - Other variation B.I.a.4.z - Change to in-process applied during the manufacture variation B.I.b.1.c - Change in the and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.c - Change in the and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.c - Change in the and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.d - Change in the   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

| material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.d - Change in the and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.2.d - Change in test starting material/reagent/intermediate change to or replacement biological/immunological/immunochemical method or a method using biological AS B.I.b.2.e - Change in test starting material/reagent/intermediate changes to a test procedure or addition) for the AS material/intermediate B.I.b.2.e - Change in test starting material/reagent/intermediate changes to a test procedure or addition) for the AS material/intermediate B.I.b.2.e - Change in test starting material/reagent/intermediate changes to a test procedure or addition) for the AS material/intermediate B.I.b.2.e - Change in test starting material/reagent/intermediate   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                     | or addition) for the AS or a starting material/intermediate B.I.c.1.b - Change in immediate packaging of the AS - Qualitative and/or quantitative composition for sterile and non-frozen biological/immunological ASs B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure   |            |     |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10501 /201805 | Periodic Safety Update EU Single assessment - pandemic influenza vaccine (H5N1) (live attenuated, nasal)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 29/11/2018 | n/a | PRAC Recommendation - maintenance |
| WS/1499             | This was an application for a variation following a worksharing procedure according to Article 20 of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 22/11/2018 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|         | Commission Regulation (EC) No 1234/2008. B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                                                                                                                                                                                                                                                     |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0015 | Update of section 4.6 of the SmPC with regard to pregnancy information based on cumulative review of pregnancy data from clinical trials, published literature and MAH pharmacovigilance database. The MAH took the opportunity to include editorial changes in section 4.8 and 5.1 of the SmPC. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 26/07/2018 | 17/04/2019 | SmPC | There are no data available on the use of Pandemic influenza vaccine H5N1 AstraZeneca in pregnant women. There is a moderate amount of data from the use of Fluenz Tetra in pregnant women, which is considered relevant to the Pandemic influenza vaccine. In more than 300 case reports in the MAH's safety database of vaccine administration to pregnant women, no unusual patterns of pregnancy complications or foetal outcomes were observed. |
| IG/0954 | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                      | 13/07/2018 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| WS/1395 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                     | 28/06/2018 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| R/0011  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                            | 22/02/2018 | 04/04/2018 |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IG/0907 | B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits                                                                                                                                                                                                                                                                                     | 26/03/2018 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| IB/0012             | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                  | 01/03/2018   | n/a   |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| II/0009/G           | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product                                                           | 25/01/2018   | n/a   |                                   |
| PSUSA/10501 /201705 | Periodic Safety Update EU Single assessment - pandemic influenza vaccine (H5N1) (live attenuated, nasal)                                                                                                                                                                                                                                                                                                                                             | 30/11/2017   | n/a   | PRAC Recommendation - maintenance |
| IA/0010/G           | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) | 05/10/2017   | n/a   |                                   |

<div style=\"page-break-after: always\"></div>

| IA/0008/G           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)   | 20/09/2017   | n/a        |                        |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------------------------------|
| T/0005              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 27/05/2017   | 23/06/2017 | SmPC, Labelling and PL |                                   |
| PSUSA/10501 /201611 | Periodic Safety Update EU Single assessment - pandemic influenza vaccine (H5N1) (live attenuated, nasal)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 09/06/2017   | n/a        |                        | PRAC Recommendation - maintenance |
| IAIN/0006           | A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 24/05/2017   | 23/06/2017 | SmPC, Labelling and PL |                                   |
| R/0003              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 23/02/2017   | 20/04/2017 |                        |                                   |
| IB/0002/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 14/01/2017   | 20/04/2017 | SmPC                   |                                   |

<div style=\"page-break-after: always\"></div>

|           | B.II.d.1.b - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits for medicinal products subject to OCABR C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                               |            |     |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IA/0001/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.II.c.3.z - Change in source of an excipient or reagent with TSE risk - Other variation | 25/11/2016 | n/a |